New MeMed BV test could save €80M in Europe by cutting unnecessary hospital stays and tests.

Beckman Coulter Diagnostics has received CE marking for the Access MeMed BV assay, a rapid test that differentiates bacterial from viral infections in about 20 minutes using existing lab equipment. This test helps doctors make better treatment decisions, reducing unnecessary antibiotic use, hospital admissions, and diagnostic tests. Economic models suggest that widespread adoption across European health systems could save up to €80 million annually by avoiding unnecessary costs related to lower respiratory infections and pneumonia. The test's availability on Beckman Coulter's immunoassay analyzers enables scalable, efficient implementation in routine clinical care.